

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, DC 20549

FORM 8-K

CURRENT REPORT  
Pursuant to Section 13 or 15(d)  
of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): March 11, 2022

**Enzo Biochem, Inc.**  
(Exact Name of Registrant as Specified in Its Charter)

**New York**  
(State or Other Jurisdiction of Incorporation)

001-09974  
(Commission File Number)

13-2866202  
(IRS Employer  
Identification No.)

527 Madison Avenue  
New York, New York  
(Address of Principal Executive Offices)

10022  
(Zip Code)

(212) 583-0100  
(Registrant's Telephone Number, Including Area Code)

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions *see* General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Securities registered pursuant to Section 12(b) of the Act:**

<b>Title of Each Class</b>	<b>Trading Symbol</b>	<b>Name of Each Exchange on Which Registered</b>
Common Stock, \$.01 par value	ENZ	The New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-1 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 5.03 Amendments to Articles of Incorporation or By-Laws; Change in Fiscal Year.**

On March 11, 2022, the Board approved an amendment (the "Bylaw Amendment") to the Company's amended and restated by-laws to permit the Board to adjourn a duly convened meeting of the Company's stockholders. The Board may make such a determination pursuant to a resolution of the Board.

The foregoing description is not complete and is qualified in its entirety by reference to the full text of the Bylaw Amendment, a copy of which is attached hereto as Exhibit 3.1 and incorporated herein by reference.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits

<b>Exhibit Number</b>	<b>Description</b>
3.1	<a href="#">Amendment No. 2 to Amended and Restated By-Laws of Enzo Biochem, Inc., effective as of March 11, 2022</a>
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ENZO BIOCHEM, INC.

Date: March 18, 2022

By: /s/ David Bench  
David Bench  
Chief Financial Officer

**AMENDMENT NO. 2 TO AMENDED AND RESTATED BY-LAWS  
OF  
ENZO BIOCHEM, INC.**

(a New York corporation)

Article I, Section 8 of the Amended and Restated By-Laws of Enzo Biochem, Inc. is hereby amended and replaced with the following:

Section 8. Order of Business. The order of business at all meetings of the shareholders shall be as determined by the chairman of the meeting. The Board may adjourn or postpone any shareholder meeting from time to time whether or not a quorum is present at such meeting.

\* \* \*